UNITE4TB Annual Meeting 2025: KNCV TB Plus supports progress in Digital Adherence Technologies
As a Consortium member of UNITE4TB, KCNV TB Plus leads the work done on Digital Adherence Technologies.
Picture credits: UNITE4TB
From 6 to 8 May 2025, the UNITE4TB Consortium gathered in London for its Annual Meeting, an event to celebrate recent progress, strengthen collaboration and network, and set the direction for the upcoming phases of the project. Hosted across three venues, the Wellcome Collection, the Royal College of Physicians, and UCL’s MRC Clinical Trials Unit, this annual meeting marked a key moment not only in the progress of the project, but also in the fight against tuberculosis (TB) in the region and worldwide.
Over the course of three dynamic days, participants not only shared the advancements within their own work packages but also engaged in discussions that strengthened the collaborative approach of the project, a value that KNCV TB Plus resonates with.
KNCV at the UNITE4TB Annual Meeting
As a proud partner in the consortium, KNCV TB Plus was pleased to join discussions and share updates from the Work Package we lead on Digital Adherence Technologies (DATs) interventions. On Consortium Day, held at the Wellcome Collection, Kristian van Kalmthout, leading DAT-related projects at KNCV, presented progress from the PARADIGM4TB trial, where smart pill boxes are now being deployed across trial sites. These digital tools are supporting people on TB treatment while enabling real-time, consistent monitoring, a vital step toward improving adherence and treatment outcomes.
The presentation highlighted:
- High adherence rates among trial participants using smart pill boxes.
- Smooth site operations across diverse settings.
- Strong on-site engagement and collaboration between work packages and local teams.
This cross-cutting collaboration is one of the project’s greatest strengths, essential in a complex, multi-country platform trial like UNITE4TB.
The Scientific Day, held at the Royal College of Physicians, offered insights into innovative research, including early results from ongoing trials, academic discoveries, and the evolving TB drug pipeline. Key sessions emphasized the need for inclusivity in clinical trials, particularly for under-studied populations, and reinforced the importance of global collaboration in accelerating TB care innovation.
Closing the meeting, Consortium Coordinator Derek Sloan noted, “There has been so much progress to share that it has been hard to fit it all into just a few days.”
Looking Ahead
For KNCV TB Plus, the Annual Meeting reaffirmed our commitment to person-centred digital health innovation and to partnerships that also place person-centred care and scientific rigor at the heart of TB research. We are proud to be part of this ambitious effort to transform TB treatment and are excited for the continued momentum as the project enters its next phase.
Photo credits: UNITE4TB
